n Publication number:

0 294 349

(12)

#### **EUROPEAN PATENT APPLICATION**

(2) Application number: 88850188.9

2 Date of filing: 30.05.88

(s) Int. Cl.4: C 12 N 15/00

C 12 N 1/20, C 12 P 21/02,

C 07 K 13/00

//(C12N1/20,C12R1:19)

30 Priority: 01.06.87 SE 8702272

Date of publication of application: 07.12.88 Bulletin 88/49

Designated Contracting States:
 AT BE CH DE ES FR QB QR IT LI LU NL SE

(7) Applicant: ALFA-LAVAL AGRI INTERNATIONAL AB Farm Center P.O. Box 39 S-147 00 Tumba (SE)

(7) Inventor: Höök, Magnus 4734 Bridge Water Road Birmingham Alabama 35243 (US) Lindberg, Martin Kjell Kornvägen 5 S-752 57 Uppsala (SE)

Signäs, Lars Christer Hamnesplanaden 2A S-753 23 Uppsala (SE)

Wadström, Torkel Mikael Rektorsvägen 7 S-223 67 Lund (SE)

Fröman, Gunnar Lindsbergsgatan 5B S-752 40 Uppsala (SE)

(7) Representative: Inger, Lars Ulf Bosson
L + U INGER Patentbyra AB Garvaregatan 12
S-262 00 Ängelholm (SE)

The microorganism(s) has (have) been deposited with Deutsche Sammlung von Mikroorganismen under number(s) DSM 4124.

A fibronectin binding protein as well as its preparation.

(g) The present invention relates to a new recombinant hybrid-DNA-molecule comprising a nucleotide sequence from S. aureus coding for a protein, or polypeptide, having fibronectin binding properties.

EP 0 294 349 A2

Vel Lys Ash Ash Leu Arg Tyr Gly Ile Arg Lys His Lys Leu Gly Ala TGCATTTATTAAGTTTAAAAAATTAATGAATTTTGCATTTAAAGGGAGATATTATA GTG AAA AAC AAT CTT AGG TAC GGC ATT AGA AAA CAT AAA TTG GGA GCA -21 104 Als Ser Val Phe Leu Gly Thr Het Ile Val Val Gly Het Gly Gin Asp Lys Glu Als Als Als Ser Glu Gin Lys Thr Thr Thr Val Glu GCA TCA GTA TTC TTA GGA ACA ATG ATG GTT GTT GGG ATG GGA CAA GAC AAA GAA GCT GCA GCA TCA GAA CAA AAG ACA ACT ACA GTA GAA GIU ASN GLY ASN SOT ALA THE ASP ASD LYS THE SOE GIU THE GIN THE THE ALA THE ASN VAL ASN HIS ILO GIU GIU THE AFG SOE TYE GAA AAT GGG AAT TCA GCT ACT GAT AAT AAA ACA AGT GAA ACA CAA ACA ACT GCA ACT AAC GTT AAT CAT ATA GAA GAA ACT CGA TCA TAT 40 284 ASH ALS THE VAL THE GIU GID PEO SOE ASH ALS THE GID VAL THE THE GIU GIU ALA PEO LYS ALA VAL GID ALA PEO GID THE ALA GID AND GEN ACA GEN ACA GEN CAN CON TEN AND GEN ACH ACH ACH ACH ACH ACH AC 70 174 PIO ALS ASE THE GIV THE VALLEYS GIV GIV VAL VALLYS GIV GIV ALA LYS PEO AFG VALLEYS GIV THE THE GIR SEE GIR ASE ASE SEE CCA GCA AAT ATA GAA ACA GTT AAA GAA GAG GTA GTT AAG GAA GAA GCG AAA CCT CGA GTT AAG GAA ACA ACA ACA TOT CAA GAC AAT AGC 100 464 ily Asp din Asg Gin val Asp Leu Thr Pro Lys Lys Ala Thr din Asm din val Ala Giu Thr din val diu val Ala din Pro Arg Thr GOA GAT CAA AGA CAA GTA GAT TTA ACA CCT AAA AAG GCT ACA CAA AAT CAA GTC GCA GAA ACA CAA GTT GAA GTG GCA CAG CCA AGA ACG Ale Ser Glu Ser Lys Pro Arg Vel Thr Arg Ser Ale Asp Vel Ale Glu Ale Lys Glu Ale Ser Ash Ale Lys Vel Glu Thr Gly Thr Asp GCA TCA GAA AGT AAG CCA CGT GTG ACA AGA TCA GCA GAT GTA GCG GAA GCT AAG GAA GCT AGT AAC GCG AAA GTC GAA ACG GGT ACA GAT Val Thr Ser Lys Val Thr Val Glu fle Gly Ser Tle Glu Gly His Ash Ash Thr Ash Lys Val Glu Pro His Ala Gly Glh Arg Ala Val GTA ACA AGT AAA GTT ACA GTA GAA ATT GGT TCT ATT GAG GGG CAT AAC AAT AAA GTA GAA CCT CAT GCA GGA CAA CGA GCG GTA LOU LYS TYP LYS LOU LYS Pho Glu Ash Gly Lou His Gln Gly Asp Typ Pho Asp Pho The Lou Sor Ash Ash Tab Ash The Bis Gly Val CTA AAA TAT AAG TTG AAA TTT GAG AAT GGT TTA CAT CAA GGT GAC TAC TTT GAC TTT ACT TTA TCA AAT AAT GTA AAT ACG CAT GGC GTA 824 Ser the Ala Arg Lys Val Pro Glu fle Lys Asn Gly Ser Val Val Het Ala the Gly Glu Val Leu Glu Gly Gly Lys fle Arg Tye The Tea art get aga aga get eeg gaa art aga aat gge tea gte gta arg geg aca ggt gaa get tea gga ggt gga aag art aga Phe The Ash Asp fie Gin Asp Lyd Val Asp Val The Ale Giu Leu Giu Ile Ash Leu Phe Ile Asp Pro Lys The Val Gin The Ash Git Ach Act GAA AC 280 1004 AGE GIR THE IIE THE SEE THE LEU ASE GIU GIU GIR THE SEE LYS GIU LEU ASE VAI LYS TYE LYS ASE GIY IIE GIY ASE TYE TYE ALA
ART CAR ACT ATA ACT TOR ACE OTE ART GRA GRA CAR ACT TOR ARG GRA TTA GRT GTT ARA THE ARA GRT GGT ATT GGG ART THE TAT GGC ASD LOU ASD GLY SET ILE GLU THE PRE ASD LYS ALE ASD ASD ASD FOR SET BLS VAL ALE PRE ILE LYS PEO ASD ASD GLY LYS THE THE ART TEA ART GGA TCG ATT GAG ACC ART ART ARA GGG ART ART AGA TTT TCG CAT GTT GCA TTT ATT ARA CCT ART ART GGT ARA ACG ACC Ser Val Thr Val Thr Gly Thr Geu Het Lys Gly Ser Asm Glm Asm Gly Asm Glm Pro Lys Val Arg Ile Phe Glu Tyr Leu Gly Asm Asm Add GTG ACT GTT ACT GGA ACT TTA ATG ANA GGT AGT AGT CAG AAT GGA AAT CAA ACA CCA AGA GTT AGG ATA TTT GGA TAC TTG GGT AGT AAT AAT GIU ASP THE ALC LYS SET VAI TYT ALS ASM THT THT ASP THT SET LYS PHE LYS GIU VAI THT SET ASM HET SET GIY ASM LEU ASM LEU GAA GAC ATA GCG AAG AGT GTA TAT GCA AAT ACG ACA GAT ACT TCT AAA TTT AAA GAA GTC ACA AGT AAT ATG AGT GGG AAT TTG AGT TTA 400 1364 Gin han asn Gly for tyr for Lou asn ile Glu asn Lou hap Lys thr tyr Val Val His tyr asp Gly Glu tyr Lou asn Gly thr asp Caa aat aat gga agg tat tca ttg aat ata gaa aat cta gat ara act tat gtt gtt gat gat gat gat gag tat tta aat ggt act gat GIU VAI ASP PHO ACG THE GIN HOT VAI GIY HIS PEO GIU GIN LOU TYE LYS TYE TYE TYE ASP ACG GIY TYE THE LOU THE TEP ASP ASR GAA GIT GAT TIT AGA ACA CAA ATG GTA GGA CAT CCA GAG CAA CIT TAT AAG TAT TAT GAT AGA GGA TAT ACC TTA ACT TGG GAT AAT GIT LEW VAL LEW TYT SET ASH LYS ALD ASH GLY ASH GLU LYS ASH GLY PTO THE THE GLU ASH ASH LYS PHE GLU TYT LYS GLU ASP THE GOT TTA GTT TTA TAC AGT AAT AAA GCG AAC GGA AAT GAG AAA AAT GGT CCG ATT ATT CAA AAT AAA TTT GAA TAT AAA GAA GAT ACA II. LYS GIU THE LOU THE GIY GIR TYE ASP LOU ASP LOU VOI THE THE VAL GIU GIU GIU TYE ASP SOF SOF THE LOU ASP IIO ASP TYE
ARE AND AND ACT CTT ACA GOT CAR TAE GAT AND ARE THA GTA ACT ACT GIT GAR GAG GAA TAE GAT TCA TCA ACT CTE GAC ATT GAT TAE 520 1724 HI: The Ala Ile Asp Gly Gly Gly Gly Tyr Val Asp Gly Tyr Lie Glu Thr Ile Glu Glu Thr Asp Ser Ser Ala Ile Asp Ile Asp Tyr CAC ACA GCT ATA GAT GGT GGA GGT GGA TAT GTT GAT GGA TAC ATT GAA ACA ATA GAA ACG GAT TCA TCA GCT ATT GAT ATC GAT TAC 550 1814 His the Ala Val ago see Giu ala Gly His Vel Gly Gly Tye the Glu see See Glu Glu See Am Peo Ile asp Phe Glu Glu See The Caf act uct utg gat ago gaa goa gut cac git gga gga tac act gag too tot gag gaa toa aat gaz eta att gac tit gaa gaa tot aca 580 1904 HIS GIU ASH SET LYS HIS HIS AIR ASP VAI VAL GIU TYT GIU GIU ASP THT ASH FTO GIY GIY GIY GIO VAL THT THT GIU SET ASH LEU CAT GAA AAT TCA AAA CAT CAC GCT GAT GTT GTT GAA TAT GAA GAA GAT ACA AAC CCA GGT GGT GGT CAG GTT ACT ACT GAG TCT ACC TTA 610 1994 Val Glu Phe Asp Glu Glu Ser The Lys Gly Ile Val The Gly Als Vel Ser Asp His The The Val Glu Asp The Lys Glu Tye The The GTT GAA TIT GAC GAA GAG TCT ACA AAA GGT ATT GTA ACT GGC GCA GTG AGC GAT CAT ACA ACA GTT GAA GAT ACG AAA GAA TAT ACA ACT 640 2084 Glu Ser Asn Leu Ile Glu Leu Val Asp Glu Leu Pro Glu Glu His Gly Gln Ale Gln Gly Pro Vel Glu Glu Ile Thr Lys Asn Asn His Gaa agt aat cig att gaa tra gig gat gaa tra cct gaa gag cat ggt caa gga cga gga gga att act aaa aac aat cat HIS ILE SET HIS SET CLY LEU GLY THE CLU ASE CLY HIS CLY ASE TYE ASE VAL ILE CLU GLU ILE CLU ASE SET HIS VAL ASE ILE CAT ATT TOT CAT TOT GGT TTA GGA ACT GAR AAT GGT CAC GGG AAT TAT GAC GTG ATT GAR GAR ATC GAR GAR AAT AGC CAC GTT GAT ATT 700 2264 LYS SOR GIU LOU GIY TYY GIU GIY GIY GIU ASH SOR GIY AON GIN SOR PHO GIU GIU ASP THY GIU GIU ANP LYS FYG LYS TYY GIU GIN AAG AGT GAA TTA GGT TAT GAA GGT GGC CAA AAT AGC GGT AAC CAG TCA TTC GAG GAA GAC ACA GAA GAA GAC AAA CCT AAA TAT GAA CAA 710 2354 Gly Gly Asn Ile Val Asp Ile Asp Phe Asp Ser Val Pro Glm Ile Eis Gly Gln Asn Lys Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu GGT GGC AAT ATC GTA GAT ATC GAT TTT GAT AGT GTA CCT CAA ATT CAT GGT CAA AAT AAA GGT AAT CAG TCA TTC GAG GAA GAT ACA GAA LYS ASP LYS Pro LYS TYR GIU BIS GLY GLY ASB ILE ILE ASP ILE ASP PHE ASP SER VAL PRO BIS ILE HIS GLY PHE ASB LYS BIS THR ABA GAC ABA CCT ABG TAT GAB CAT GGC GGT ABC ATC ATT GBT ATC GBC TTC GBC AGT GTG CCA CAT ATT CAC GGB TTC ABT AGG CAC ACT GIU IIE IIE GIU GIU ASP THE ASE LYS ASP LYS PEC SOF TYF GIN PHO GIY GIY HIS ASE SOF VAL ASP PHO GIU GIU ASP THE LOU PEC GAA ATT ATT GAA GAA GAT ACA AAT AAA GAT AAA CCA AGT TAT CAA TIC GGT GGA CAC AAT AGT GTT GAC TIT GAA GAA GAT ACA CIT CCA Lys Val Ser Gly Gin Ash Glu Gly Gin Gin The Ile Glu Glu Asp The Tre Pro Pro Ile Val Pro Pro The Pro Pro The Pro Glu Val 850 2714 Pro Set Glu Pro Glu Thr Pro Thr Pro Pro Thr Pro Glu Val Pro Ser Glu Pro Glu Thr Pro Thr Pro Thr Pro Glu Val Pro Ser CCA AGT GAG CCG GAA ACA CCA ACG CCA ACA CCA ACA CCA AGA GTA CCA AGT GAG CCG GAA ACA CCA ACA CCA ACA CCA GAA GTG CCG AGT GIU PEO GIU THE PEO THE PEO PEO THE PEO GIU VAI PEO ALA GIU PEO GIY LYS PEO VAI PEO PEO ALA LYS GIU GIU PEO LYS LYS PEO
JAG CCA GAA ACT CCA ACA CCG CCA ACA CCA GAG GTA CCA GCT GAA CCT GGT AAA CCA GTA CCA CCT GCC AAA GAA GCA CCT AAA AAG CCT Sec Lys Pro Val Glu Glu Gly Lys Val Val The Pro Val fle Glu fle asm Glu Lys Val Lys Ala Val Ala Pro The Lys Lys Pro Glu TCT AAA CCA GTG GAA CAA GGT AAA GTA GTA ACA CCT GTT ATT GAA ATC AAT GAA AAG GTT AAA GCA GTG GCA CCA ACT AAA AAA CCA CAA See Lys Lys See Glu Leu Pro Glu Thr Gly Gly Glu Glu See Thr Asa Lys Gly Met Leu Phe Gly Gly Leu Phe See Ile Leu Gly Leu TCT ARG ARA TCT GRA CTA CCT GRA ACA GGT GGA GRA GRA TCA ACA ARA GGT ATG TTG TTC GGC GGA TTA TTC AGC ATT CTA GGT TTA 970 3074 Ala Leu Leu Arg Arg Asn Lys Asn Bis Lys Ala \*\*\* GCA TTA TTA CGC AGA AAT AAA AAG AAT CAC AAA GCA TAA TAAACAAAAATTGACGGGTTTATTTCATAAATTATATGAAGTAAGGCTTGTTTTTTATATTAAATCAA ATTICTANIAGAMATTAGAGTOTTTTCTGATTGCTTTATTGGTTTATGTTGTTGATGATGATGATGATGAGAGCTGAGAGATAAGTTAGAGTATTAAACTAG 1280

#### **Description**

0 =

#### A FIBRONECTIN BINDING PROTEIN AS WELL AS ITS PREPARATION.

#### Technical field

5

10

20

25

30

35

40

50

55

The present invention relates to a fibronectin binding protein as well as hybrid-DNA-molecules, e.g. plasmids or phages comprising a nucleotide sequence coding for said protein. Further the invention relates to microorganisms comprising said molecules and their use producing said protein, as well as the synthetic preparation of said protein.

The object of the present invention is to obtain a minimal fibronectin binding protein.

A further object is to obtain said protein by means of a genetic engineering technique by using e.g. a plasmid comprising a nucleotide sequence coding for said protein.

A further object is to obtain a possibility of preparing said protein by chemical synthesis.

Further objects will be apparent from the following description.

#### 15 Background of the invention

WO-A1-85/05553 discloses bacterial cell surface proteins having fibronectin, fibrinogen, collagen, and/or laminin binding ability. Thereby it is shown that different bacteria have an ability to bind to fibronectin, fibrinogen, collagen, and/or laminin. It is further shown that fibronectin binding protein has a molecular weight of 165 kD and/or 87 kD, whereby it is probable that the smaller protein is a part of the larger one.

Fibronectin is a large glycoprotein (Mr ca 450 kd) with two similar subunits, which may vary in moleclar size depending on a complex splicing pattern of a precursor mRNA (1). The major function of fibronectin, which is found in body fluids, blood clots and extracellular matrices, seems to be related to the ability of the protein to mediate substrate adhesion of most eukaryotic cells (2, 3, 4, 5.)

In the late seventies, Kuusela found that fibronectin not only interacts with eucaryotic cells but also binds to cells of Staphylococcus aureus (6). Since this observation, a number of pathogenic microorganisms have been shown to bind to fibronectin with a high degree of specificity and a high affinity (7). Fibronectin in the extracellular matrix appears to serve as a substratum also for the adhesion of different microorganisms. The binding of fibronectin may for some microorganisms represent a crucial step in the colonization of host tissue and development of infection.

Several different cell surface components have been implicated as fibronectin receptors on Gram-positive bacteria including lipotechioc acid (8, 9) and protein (10). In previous studies a fibronectin binding protein with a M<sub>r</sub> of 197-210 kD has been isolated from <u>S. aureus</u> strain Newman (11, 12) and tentatively identified as a fibronectin receptor. To further characterize this fibronectin binding protein from <u>S. aureus</u>, the gene for this protein has been cloned in <u>E. coli</u>. The fibronectin binding domain within this protein has also been localized and the behaviour of a fusin protein containing this domain and IgG-binding regions of protein A will be disclosed below.

#### Description of the invention.

It has now surprisingly been found possible to obtain a hybride-DNA-molecule comprising a nucleotide sequence coding for a protein or a polypeptide having fibronectin binding properties. As evident from below the following nucleotide sequence is present in the gene coding for said protein:

The invention further comprises a plasmid or phage comprising a nucleotide sequence coding for said fibronectin binding protein.

The invention further comprises a microorganism comprising at least one hybrid-DNA-molecule according to the above.

The invention further comprises a method for producing a fibronectin binding protein whereby at least one hybrid-DNA-molecule of above is introduced into a microorganism, cultivating said microorganism in a growth medium, and isolating the protein thus formed by means of an affinity chromatography on a fibronectin bound to an insolubilized carrier followed by ion exchange chromatography.

A further aspect of the invention comprises a chemical synthesis of the fibronectin binding protein, whereby an amino acid sequence is built up based on said nucleotide sequence encoding for said protein starting from the C-terminal histidine which is stepwise reacted with the appropriate amino acid, whereby it is finally reacted with glycine at the N-terminal end, to form the fibronectin binding peptide region.

Appropriate carrier proteins can be coupled to the amino acid sequence as well, such as IgG binding

regains of protein A.

The invention will be described in the following with reference to the examples given, however, without being restricted thereto.

Example 1

5

10

15

20

25

30

40

45

Screening of a gene bank for fibronectin binding protein (FNBP)

A gene bank in plasmid pBR322 of chromosomal DNA from Staphylococcus aureus strain 8325-4 earlier described by (13) was screened for clones expressing FNBP. E. coli clones were lysed and the lysates were tested for their ability to inhibit the binding of <sup>125</sup>-I-fibronectin to cells of S. aureus Cowan I as described in the method section. To simplify screening the clones were pooled in lots of 25, lysed and tested. Out of the 22 pools tested, the one with the highest inhibitory activity was retested in 5 pools of 5. Finally, the individual clones in one positive pool were tested resulting in the isolation of one single positive clone. The plasmid in the positive clone was called pFR001.

This plasmid pFR001 in an E. coli strain 259 has been deposited at the Deutsche Sammlung von Mikroorganismen (DSM) and has thereby been allocated the deposition number 4124.

Isolation of the Staphylococcal FNBP from E. coli pFR001

The E.coli clone, positive for FNBP, was grown in LB-medium at 37°C to the stationary growth phase. The bacterial cells were centrifuged and lysed by an osmotic shock procedure (14). To exclude that inhibitory effect of the shock lysate on the binding of <sup>125</sup>I-fibronectin to S.aureus cells is due to proteolytic activity,lysate was added to the Incubation mixture and the amount of <sup>125</sup>I-fibronectin bound to S.aureus was determined after 1,2,3, and 4 hrs of incubation. Throughout this incubation period, the level of inhibition caused by the lysate remained constant (e.g. 50%) suggesting that the observed inhibition was not due to a progressive degradation of the <sup>125</sup>I-labelled ligand or corresponding receptor.

If the inhibitory activity is due to the presence of FNBP-like structures in the lysate, these should express a specific affinity for fibronectin. The lysate, was therefore analysed by affinity chromatography on a column of fibronectin-Sepharose as described in Materials and Methods (Fig. 1A). The purification was about 30 fold. Further fractionation was achieved by subjecting the affinity purified material to ion-exchange chromatography using a mono Q column fitted on to a FPLC-system. In this fractionation step two major peaks were obtained (Fig. 1B). Analyses by polyacrylamide gel electrophoresis indicated that the two peaks contained proteins of molecular weights 165 and 87 kD, respectively (Fig. 2). Both components inhibited the binding of 1251-fibronectin to S.aureus. The fraction containing the 165 kD protein had a specific inhibitory activity of 220 units/qg representing a 430-fold purification from the original shock lysate and it was 30 times more active than the 87 kD protein on a molar basis (data not shown).

Amino acid analysis of the two proteins showed that they had a very similar amino acid composition which also closely resembled that determined for the native FNBP isolated from S.aureus strain Newman (Table 1). The immuological relationship of 165 kD protein isolated from E.coli pFR001 to the native FNBP isolated from S.aureus strain Newman was analyzed. The 165 kD protein was <sup>125</sup>I-labelled and Immunoprecipitated with Increasing dilutions of an antibody to S. aureus strain Newman. A 300-fold dilution of the antiserum precipitated 50% of the <sup>125</sup>I-labelled protein. Unlabelled 165 and 87 kD proteins as well as the native FNBP interferred with the Immunoprecipitation of the labelled 165 kD protein (data not shown). These observations suggest that the 165 and 87 kD proteins isolated from S.aureus strain Newman are closely related to fibronectin binding protein (FNBP).

Identification of the region of the fnbp-gene coding for the binding activity.

The size of the insert in plasmid pFR001 is about 6.5 kbp. The restriction map of the insert is shown in Fig. 3(A). In order to determine the transcription direction and to localize the region coding for the binding function, the Pstl fragment of about 3.7 kbp was recloned in the Pstl site of pBR322. This results in loss of the ampicillin resistance phenotype conferred by this plasmid. Eight such clones were obtained, five of which were positive and three negative for fibronectin binding activity. One of each was tested for the orientation of the Pstl fragment. The plasmid of the positive clone pFR004 had the EcoRl site closest to the Amp-promoter and that of the negative clone had the reverse orientation. These data indicated that the transcription orientation is from EcoRl to Pstl on the 3.7 kbp EcoRl - Pstl fragment and that at least a part of the fnbp-gene, which codes for the binding function, is located on this fragment. To verify this, the Amp-promoter in pFR004 was removed by EcoRl digestion followed by religation of the plasmid. The resulting plasmid pFR008 does not express fibronectin binding activity. In pFR001 the endogenous promoter is thus presumably located somewhere on the left hand side of the EcoRl site as indicated by the arrow in Fig. 3A). By a plasmid construction (not described in detail here) the EcoRl (in the insert)-Sall (in pBR322) fragment from pFR001 was introduced into pFR008. The fibronectin binding activity was then regained, due to the restoration of the endogenous promoter from the fnbp-gene.

Knowing the transcription direction of the <a href="mailto:fnbp-gene">fnbp-gene</a> (from left to right as drawn in Fig. 3(A)) fusions were made to the gene for staphylococcal protein A. An expression/secretion vector called pRIT3 based on the protein A gene with restriction enzyme multilinker has been constructed (15). The multi-linker is placed immediately downstream of the last IgG-binding region, thus eliminating the C-terminal cellwall binding region

of protein A. The 3.7 kbp EcoRI-Pstl fragment from pFR001 was inserted into this vector expecting it to encode a protein A-FNBP fusion protein, providing the reading frame was correct. This was obviously the case since the clone containing this plasmid, called pFR013, is positive in tests for both protein A and FNBP.

Plasmid pFR013 was treated with exonuclease Bal31 in order to identify a region smaller than the 3.7 kbp insert coding for the fibronectin binding activity. The plasmid was cleaved with EcoRI or Pst1 (at the 5' and the 3'end of the coding region, respectively), treated for various times with Bal31 and religated. During ligations a 20-fold excess of an EcoRI linker was added in oder to introduce EcoRI sites at new positions. Fig. 3(C) shows the deletions obtained from either the 3' or the 5' end and the corresponding fibronectin binding activity. A region of the gene of about 700 bp coding for binding activity is located between the end points of deletions number 56 (deletion from the 5 énd) and number 22 (deletion from the 3 énd). From deletion plasmid number 56, the 900 bp region from the newly introducted EcoRI site to the Pvull site was subcloned. This fragment was cloned into pUC18 cleaved with EcoRI and Smal. The resulting plasmid, which encodes a fusion protein with both β-galactosidase and fibronectin binding activity, is called pFR015. The fragment can be recloned from pFR015 by EcoRI and BamHI cleavages because of the multilinker in pUC18.

Restriction fragments were also subcloned as indicated in Fig. 3(B). In the case of <a href="EcoRI-Psti">EcoRI-Clal fragments</a> the protein A expression vector pRIT3 was used. Fragments <a href="Ball-Pvuil">Ball-Pvuil</a> and <a href="Ball-Puil">Ball-Pvuil</a> and <a href="Ball-Puil">Ball-HincII</a> were subcloned and expressed in pUC18. In all cases, except for the <a href="EcoRI-Clal fragment">EcoRI-Clal fragment</a>, fusion proteins with fibronectin binding activity were obtained. The negative result in the case of the <a href="Clal-Clal subclone may be due to the Insert appearing in the wrong reading frame">EcoRI-Clal fragment</a>, fusion proteins with fibronectin binding activity were obtained. The negative result in the case of the <a href="Clal-Clal subclone may be due to the Insert appearing in the wrong reading frame">EcoRI-Clal fragment</a>, fusion proteins with fibronectin binding activity were obtained. The negative result in the case of the <a href="Clal-Clal subclone may be due to the Insert appearing in the wrong reading frame">EcoRI-Clal fragment</a>, fusion proteins with fibronectin binding activity were obtained. The negative result in the case of the <a href="Clal-Clal subclone may be due to the Insert appearing in the wrong reading frame">EcoRI-Clal fragment</a>, fusion proteins with fibronectin binding activity were obtained. The negative result in the case of the <a href="Clal-Clal subclone may be due to the Insert appearing in the wrong reading frame">EcoRI-Clal fragment</a>, fusion proteins with the case of the <a href="Clal-Clal subclone may be due to the Insert appearing in the wrong reading frame">EcoRI-Clal subclone may be due to the Insert appearing in the wrong reading frame</a>.

#### Production and characterization of a fusion protein, ZZ-FR

L =

15

20

25

35

45

50

65

The yield of the 165 kD protein (Fig.2) from an osmotic shock lysate of E. coli HB101 cells carrying the plasmid pFR001 was approximately 40 µg per liter culture medium. Even if there were losses due to degradation of the high molecular weight compound during the purification all data indicated that the inbp-gene with the endogenous promoter is weakly expressed in E. coli. In order to improve the level of expression we used a recently developed expression system, which allows heterologous proteins to be secreted to the growth medium of E. coli (16). The plasmid vector used, pEZZ318, contains two syntetic, sligtly modified IgG-binding domains of the gene for staphylococcal protein A preceded by the promoter and signal sequence of the same gene. A Ball-Pvull fragment of approximately 600 bp of the inbp-gene (Fig. 3(B)) cloned in pUC18 was recloned into pEZZ318 cleaved with EcoRI and Hindlil. After ligation and transformation pEZZ-FR was isolated. This plasmid encodes a fusion protein consisting of the IgG binding product ZZ and a fibronectin binding region FR of the FNBP.

For production of the ZZ-FR protein <u>E. coli</u> strain HB101 carrying the plasmid pEZZ-FR was grown overnight in Trypticase Soy Broth. Bacteria were removed by centrifugation and the growth medium was passed through an IgG-Sepharose Fast Flow column. After washing the column with TST-buffer (50 mM Tris-HCl pH 7.4 150 mM NaCl, 0,05% Tween<sup>R</sup> 20) the ZZ-FR protein was eluted with 0,5 M acetic acid titrated to pH 2.8 using ammonlum acetate. Approximately 50 mg protein was eluted from the column per liter of growth medium applied.

After lyophilization the eluted material was analyzed by SDS-PAGE, which revealed a major protein band at approximately 63 kD (Fig. 4). In addition, bands corresponding to smaller fragments appeared, probably due to proteolytic degradation of the fusion protein. The intact protein A which was run on the same gel appeared as a diffuse band around 56 kD. The proteins in the gel were electrophoretically transferred to a nitrocellulose paper and probed with a <sup>125</sup>-I-labelled 29 kD fibronectin fragment. Fig. 4, lanes C and D, shows that the fusion protein but not intact protein A, binds the radiolabelled fibronectin fragment.

Further evidence for the fibronectin binding ability of the ZZ-FR fusion protein was obtained by affinity chromatography on a Sepharose column substituted with the 29 kD fibronectin fragment. The fusion protein was bound to the column and was eluted from the affinity matrix with 6M GuHCl (Fig. 5A). The fibronectin binding activity of the ZZ-FR fusion protein was apparently located in the FR-region since intact protein A did not bind to the affinity matrix (Fig. 5B). The portion of the ZZ-FR fusion protein preparation that did not bind to the affinity matrix consisted of proteins with M<sub>r</sub> lower than of the intact fusion protein (Fig. 6, lane A) whereas the material binding to the column consisted of an almost pure preparation of intact 63 kD ZZ-FR fusion protein (Fig. 6, lane B).

In oder to determine how much of the fibronectin binding capacity of staphylocaccal cells that can be ascribed to the cloned FNBP, the inhibitory activity of the fusion protein ZZ-FR was quantified. As shown in Fig. 7 the fusion protein totally inhibited the binding of <sup>125</sup>I-labelled 29 kD fragment as well as intact fibronectin to cells of both <u>S. aureus</u> strains Newman and 8325-4, protein A, which was used as a control, did not inhibit the binding (Fig. 7).

After the report by Kuusela (6) that <u>S. aureus</u> binds to fibronectin much work has been focused on attempts to identify the bacterial component(s) responsible for the binding. The rationale for these studies has been that binding of pathogenic bacteria to fibronectin may represent a mechanism of tissue adherence of crucial importance in the early stages of an infection. Proteins purified by affinity chromatography on immobilized fibronectin, have been implicated in the binding of staphylococcal cells to fibronectin. However the reported molecular weights of the fibronectin binding proteins vary from 18 kD (10) all the way up to 197 and 210 kD (11, 17). The main reason for the heterogeniety in molecular size may be proteolytic degradation of the proteins during the isolation procedures.

In the present disclosure the cloning in <u>E. coli</u> of a gene coding for a fibronectin binding protein from <u>S. aureus</u> strain 8325-4 is disclosed. When the <u>fnbp</u>-gene is expressed in <u>E. coli</u> from the endogenous promoter the protein can be isolated from the periplasm by osmotic shock. This indicates that not only the promoter but also the signal peptide is functional in E. coli.

Although the proteins coded for by the cloned fnbp-gene have molecular weights of 165 and 87 kD (Fig. 2), which is smaller than the FNBP Isolated from S. aureus strain Newman (M<sub>r</sub>=210kD) (12), their amino acid compositions closely resemble that of the native protein (Table 1). Furthermore, antibodies raised against the native FNBP cross-react with the 165 and 87 kD proteins. These data strongly suggest that the structure of the proteins coded for by the cloned gene from S. aureus strain 8325-4 resembles that of native FNBP from S. aureus strain Newman. The 87 kD protein may be the result of pretermination at the transcriptional or translational level or alternatively proteolytic cleavage of the 165 kD protein. At present it cannot be explained why the 165 kD protein is as much as 30 times more active than the 87 kD protein in inhibition of fibronectin binding to S. aureus cells.

By deletion mapping using Bal31-clevage and subcloning of restriction fragments the domain of the fnbp-gene encoding the fibronectin binding activity had been located to a region of approximately 350 bp (Fig. 3(B)). A fragment of the gene of approximately 600 bp covering these 350 bp was ligated directly to a tandemly repeated sequence (zz) of a synthetic IgG-binding domain of the protein A gene preceded by the protein A promoter and signal sequence in expression vector pEZZ318 (16). The resulting fusion protein (ZZ-FR), which has a molecular weight of approximately 63 kD as determined by SDS-PAGE (Fig. 4), contains 126 amino acids of the ZZ domain followed by approximately 200 amino acids encoded by the 600 bp insert from the fnbp-gene The C-terminal end of the protein consists of amino acids which are the result of an out of frame read- through into the lacZ' gene of the vector until a translation stop codon is reached. The fusion protein (ZZ-FR), which is expressed at a high level and secreted to the growth medium of E. coli, is easily isolated by affinity chromatogtaphy making use of the IgG-binding ability of the ZZ-domain.

The ZZ-FR protein was bound to the 29 kD NH<sub>2</sub>-terminal domain of fibronectin and completely inhibited the bindning of intact fibronectin to <u>S. aureus</u> (Figs. 5 and 6). These data Indicate that under the Incubation conditions used other proteins, recognizing domains outside the 29 kD N-terminus of fibronectin, are not expressed by the staphylococcal cells. Furthermore the fibronectin binding activity of the FNBP has been localized to a fairly small segment of the protein. Recent analysis of the native 210 kD FNBP Isolated from <u>S. aureus</u> strain Newman demonstrated that this protein is multivalent and one molecule of the FNBP is capable of binding 6-9 fibronectin molecules (12). The cloned <u>fnbp</u>-gene is derived from strain <u>S. aureus</u> 8325-4. If there are no differences between strains of <u>S. aureus</u> one would except the FR-region to contain several repeating sequences. This question was also answered by sequence analysis of the cloned <u>fnbp</u>-gene. The sequence of the FR-region having FNBP-properties is given in Fig. 8

25

30

40

55

60

There is reason to believe that the FR binding activity is related to the each of the three 38 amino acids repeats as the <u>Bal1-Pvull-fragment</u> encodes for a binding activity (cf. Fig. 3); as the <u>Bal1-Hincll-fragment</u> encodes for a <u>binding</u> activity; and as the <u>Hincll-Pvull-fragment</u> does not encode for <u>binding</u> activity. Furthermore, the one single 38 amino acids repeat is functional in binding fibronectin, since a synthezised 38-amino acids long peptide (38(2)-repeat) has binding ability, as shown in Fig. 9. Each of the three 38 amino acids repeats are very homologous

#### Example 2.

Chemical synthesis of a polypeptide based on the nucleotide sequence coding for the fibronectin binding domain of 38 amino acids (38(2) repeat) was performed by building up the amino acid sequence corresponding to said nucleotide sequence starting from the C-terminal histidin and stepwise reacting with the appropriate amino acid and finally reacting with the glycine at the N-terminal end, in a solid phase synthesis according to the method by K.B. Merrifield, J. Am. Chem. Soc. 86, pp.304, (1964). Hereby the polypeptide corresponding to the second 38 amino acid repeat was synthezised, as well as three further polypeptides being parts of this 38-repeat, viz: 1) the polypeptide covering amino acids 1-19, 2) the polypeptide covering amino acids 9-30, and 3) the polypeptide covering amino acids 20-38, were all synthezised according to the same method.

The fibronectin binding ability of the complete 38-repeat, as well as of the 1-19 amino acid polypeptide, the 9-30 amino acid polypeptide, the 20-38 amino acid polypeptide, as well as a mixture of these three smaller polypeptides was tested, and the result is given in Fig. 9. The fragments of the complete 38-repeat were synthezised in order to check if fibronectin binding is dependent upon the complete 38-repeat, as anticipated, or if fibronectin binding properties could be further confined to some smaller regoin of the 38 amino acid sequence. As evident from Fig. 9 the fibronectin binding property is only present in the complete 38 amino acids peptide.

#### MATERIALS AND METHODS

Bacterial strains and plasmids. A gene bank in pBR322 of chromosomal DNA from Staphylococcus aureus strain 8325-4, earlier described (13) was screened for clones expressing fibronectin binding activity. E. coli strains HB102, (18) and JM105 (19), were used in subcloning and expression experiments. The plasmid vectors used were pBR322 (20) pUC18 (21) and the protein A vectors pRIT3 (15) and pEZZ318 (16). S.aureus strains Cowan I, Newman and 8325-4 were used in the assay of the fibronectin binding protein (FNBP).

Microorganism growth medium. At the culture of E. coli bacteria the following medium was used. The amounts given relates to 1 litre of medium.

Trypton Soy Broth (Oxoid Ltd, Basingstoke, Hants, GB) 30 g

Yeast Extract (Oxold) 10 q

D-glucose 40 a

NH<sub>4</sub>Cl 2,5 g

5

10

15

20

30

40

45

Na<sub>2</sub>HPO<sub>4</sub>.2H<sub>2</sub>O 7,5 g

KH<sub>2</sub>PO<sub>4</sub> 3,0 g

2,5 g Na<sub>2</sub>SO<sub>4</sub>.10H<sub>2</sub>O

MgSO<sub>4</sub>.7H<sub>2</sub>O 0,2 g

CaCl<sub>2</sub>.2H<sub>2</sub>O 0,5 mg

FeCl<sub>3</sub>.6H<sub>2</sub>O 16,7 mg

ZnSO<sub>4</sub>.7H<sub>2</sub>O 0,18 mg

CuSO<sub>4</sub>.5H<sub>2</sub>O 0,16 mg

MnSO<sub>4</sub>.4H<sub>2</sub>O 0,15 mg

0.10 mg CoCl<sub>2</sub>

NaEDTA 20,1 mg

Assay of fibronectin binding protein (FNBP). Quantitation of fibronectin binding to cells of S. aureus has been described earlier (10). If not otherwise stated, 109 cells of S. aureus Cowan I are incubated with 125I-labelled fibronectin or the 29 kD NH2-terminal fragment of fibronectin in PBS containing 1 mg/ml bovine serum albumin in a total volume of 0,3 ml. After incubation for 2 hours at 22°C the radioactivity bound to the cells is measured in a gamma counter.

Lysates of E. coli clones prepared in Tris-HCl buffer, pH 8,1, containing lysozyme EDTA as earlier described (13), were analysed for fibronectin binding activity by measuring their ability to compete with staphylococcal cells for binding the 125I-labelled 29 kD NH2-terminal fragment of fibronectin. The amount of FNBP able to inhibit binding to 50% is considered as one unit of activity.

An osmotic shock procedure was used to release proteins from the periplasmic space of E. coli (14).

Purification of FNBP. The purification is based on affinity chromatography on fibronectin-Sepharose followed by ion-exchange chromatography.

Human fibronectin was prepared from outdated blood by the method known (22). The fibronectin was then dialysed against 20 mM Tris-HCl, pH 8,3 and concentrated on a DEAE-column. The coupling of fibronectin to Sepharose SL-4B was done by a bromocyan activation procedure as known (23).

The E. coli lysate was pumped onto the affinity column which was subsequently washed with 0.5 M ammonium acetate until the baseline was stable (about four column volumes). The FNBP was then eluted with 0,4M acetic acid and either neutralized with ammonia or lyophilized. After dialysis against 10 mM ammonium acetate with pH adjusted to 7,6 with ammonia a further fractionation step was performed by ion-exchange chromatography on a Pharmacla FPLC equipment using a mono Q column.

Nucleotide sequence analysis. The nucleotide sequence was determined in accordance with the methods described by Maxam, A.M. et al (27).

Amino acid analysis. The amino acid composition was determined using a Durrum D-500 analyzer. Samples were hydrolyzed in 6 M HCl containing 2 mg/ml phenol for 24 hours at 1100°C. One sample was also oxidized with performic acid in oder to determine cystein and methionine. Norluecin was added as an internal standard. Protein was determined according to (24) using bovine serum albumin as a standard.

Electrophoresis. If not indicated otherwise SDS-polyacrylamide gel electroporesis was performed in 5-15% gradient gels. The gels were stained with Coomassie brilliant blue, de-stained and photographed.

Radioimmunoassay procedure. The purified FNBP with an estimated molecular weight in SDS-polyacrylamide gel electrophoresis of 165 kD was labelled with 1251-odine by the chloramine-T method as known (25). After the iodinaton the material was rechromatographed on a fibronectin-Sepharose column.

The incubation mixture contained 125I-FNBP (3 400 cpm in 10 μl) was mixed with various dilutions of a rabbit antiserum (containing antibodies directed against S. aureus strain Newman), in incubation buffer (PBS, 0,1% Triton X-100 and 0,02% sodium azid) in a volume of 0,2 ml.

Samples were incubated for 2 hours at 20°C to allow antigen-antibody reaction. 0,1 ml of 10% suspension (w/v) of protein A-Sepharose in PBS was added and the mixture was incubated for another hour. The incubation was stopped by adding another 1,7 ml of incubation buffer to the samples. After centrifugation at 2000 rpm for 3 min the supernatants were sucked off. The pellets were washed twice in incubation buffer and the radioactivity associated with the protein A-Sepharose was measured in a gammacounter.

Restriction endonucleases and other enzymes. Restriction enzymes, T4 DNA ligase and Bal31 were purchased from BRL and used according to their recommendations. Other methods involving DNA techniques were essentially as known (26).

0 294 349

	Composition (mal%)						
Amino acid	210kp <sup>a)</sup>	165 kD	87 kD				
Aspartic acid/asparagine	15.4	14.6	13.4				
Threonine	9.7	10.7	10.3				
Serine	7.4	6.5	8.0				
Glutamic acid/glutamine	17.9	17.1	15.1				
Proline	6.3	6.2	5.8				
Glycine	8.9	7.9	8.4				
Alanine	5.3	4.6	4.7				
Half-cystine	0.1	0.2	n.d.				
Valine	7.2	7.8	8.6				
Methionine	0.6	0.6	n.d.				
Isoleucine	4.3	4.7	3.8				
Leucine	4.1	4.0	4-6				
Tyrosine	2.1	2.3	4.1				
Phenylalanine	2.4	2.0	3.6				
Histidine	1.0	3.2	3.0				
Lysine .	5.3	6.3	6.6				
Tryptophan	n.d.	n.d.	n.d				
Arginine	1.9	1.2	-				

a) from Fröman et al.(1987), (12).

n.d.= not determined

The presnt fibronectin binding protein can be used for immunization, whereby the protein, preferably in combination with a fusion protein to create a large antigen to respond to, is injected in dosages causing immunological reaction in the host mammal. Thus the fibronectin binding protein can be used in vaccination of ruminants against mastitis caused by Staphylococcal infections. The fibronectin binding protein of this invention has shown to form antibodies against a staphylococcal mastitis in a mouse model as shown in the Table below.

#### TABLE

10

15

20

25

50

65

30
Vaccinated
(FNBP) 30 3 8 83 10 11 9 0 0 91 0
35
Control 38 50 16 32 3 8 38 0 25 38 0

40 Mastitis: +++ = gross; ++ = medium-grade; + = low grade; 0
= no macroscopic changes;

A = consistently non-reactive, total necrosis; B = advanced regressive changes + slight inflammatory reaction; C1 = dis-seminated inflammatory reaction + local necrosis; C2 = dis-seminated inflammatory reaction; C3 = local inflammatory reaction; O = no reaction.

As evident from the Table above a consistent immunization is obtained using the FNBP as expressed by the E. coli containing the plasmid pFR001.

Further, the fibronectin binding protein can be used to block an infection in an open skin wound by wound treatment using the fibronectin binding protein in a suspension. Thus the fibronectin binding protein can be used for the treatment of wounds, e.g. for blocking protein receptors, or for immunization (vaccination). In the latter case the host body produces specific antibodies, which can protect against invasion of bacterial strains comprising such a fibronectin binding protein. Hereby the antibodies block the adherence of the bacterial strains to damaged tissue.

Examples of colonizing of a tissue damage are:

a) colonizing of wounds in skin and connective tissue, which wounds have been caused by a mechanical trauma, chemical damage, and/or thermical damage;

 b) colonizing of wounds on mucous membranes, such as in the mouth cavity, or in the mammary glands, urethra, or vagina;

c) colonizing on connective tissue proteins, which have been exposed by a minimal tissue damage (microlesion) in connection with epithelium and endothelium (mastitis, heart valve infection, hip exchange surgery).

When using the present FNBP, or the 38 amino acid polypeptide, for the purpose of immunization (vaccination) in mammals, including man, the protein, or polypeptide is dispersed in sterile, isotonic saline solution, optionally while adding a pharmaceutically acceptable dispersing agent. Different types of adjuvants can further be used in order to sustain the release in the tissue, and thus expose the protein or the peptide for a longer time to the immundefense system of a body.

A suitable dosage to obtain immunization is 0,5 to  $5 \mu g$  of FNBP, or polypeptide, per kg bodyweight and injection of immunization. In order to obtain a durable immunization, vaccination should be carried out at more than one consecutive occasions with an interval of 1 to 3 weeks, preferably at three occasions.

When using the present FNBP, or polypeptide, for topical, local administration the protein is dispersed in an isotonic saline solution to a concentration of 25 to 250 µg per ml. The wounds are then treated with such an amount only to obtain a complete wetting of the wound surface. For an average wound thus only a couple of millilitres of solution are used in this way. After treatment using the protein solution the wounds are suitably washed with isotonic saline or another suitable wound treatment solution.

Further the fibronectin binding protein as well as the minimal fibronectin binding site polypeptide, of the present invention can be used to diagnose bacterial infections caused by Staphylococci strains, whereby a fibronectin binding protein of the present invention is immobilized on a solid carrier, such as small latex or Sepharose<sup>R</sup> beads, whereupon sera containing antibodies are allowed to pass and react with the FNBP thus immobilized. The agglutination is then measured by known methods.

Further, the FNBP, or the polypeptide can be used in an ELISA test (Enzyme Linked Immuno Sorbent Assay; E Engvall, Med. Biol. 55, 193, (1977)). Hereby wells in a polystyrene microtitre plate are coated with the FNBP, and incubated over night at 4°C. The plates are then thoroughly washed using PBS containing 0.05% TWEEN 20, and dried. Serial dilution of the patient serum were made in PBS-Tween, were added to the wells, and incubated at 30°C for 1.5 hrs. After rinsing antihuman-lgG conjugated with an enzyme, or an antibovine-lgG conjugated with an enzyme, respectivel, horseradishperoxidase or an alkaline phosphatase, was added to the wells and incubated at 30°C for 1,5 hrs, whereupon when the lgG has been bound thereto, and after rinsing, an enzyme substrate is added, a p-nitrophosphate in case of an alkaline phosphatase, or ortophenylene diamine substrate (OPD) in case a peroxidase has been used, respectively. The plates comprising the wells were thus then rinsed using a clirate buffer containing 0.055% OPD, and 0.005% H<sub>2</sub>O<sub>2</sub>, and incubated at 30°C for 10 min. Enzyme reaction was stopped by adding a 4N solution of H<sub>2</sub>SO<sub>4</sub> to each well. The colour development was measured using a spectrophotometer.

Depending on the type of enzyme substrate used a fluoroscense measurement can be used as well.

Another method to diagnose Staphylococci infections is by using the DNA gene probe method based on the FNBP sequence or the 38 amino acid polypeptide sequence. Thereby the natural or synthetic DNA sequences are attached to a solid carrier, such as a polystyrene plate as mentioned above, by e.g. adding a milk in the case of diagnozing a mastitis, to the surface. The DNA gene probe, optionally labelled enzymatically, or by a radioactive isotope is then added to the solid surface plate comprising the DNA sequence, whereby the DNA gene probe attaches to the sequence where appearing. The enzyme or the radioactive isotope can then readily be determined by known methods.

Above the term fibronectin binding protein includes any of the 38 amino acid polypeptide sequences as well, which 38 amino acid polypeptide sequences forms the minimal fibronectin binding site of the complete protein.

REFERENCES 8. Beachey, E.H. and Simpson, W.A(1982). Infection 10, 107-110.

- 20. Bolivar, F., Rodriquez, R.L., Greene, P.J., Betlach, M.C., Heyneker, H.L., Boyer, H.W., Crosa, J.H. and Falkow, S. (1977). Gene, 2, 95-113.
- 18. Boyer, H.W. and Roulland-Dussolx, D. (1969). J. Mol.Biol: 41, 459-472.
- 9. Courtney, H.S., Ofek,I., Simpson, W.A., Hasty, D.L. and Beachey, E.H. (1986). Infect. Immun. 53 454-459.
- 11. Espersen, F. and Clemmensen, I. (1982). Infect. Immun. 37, 526-531.
- 17. Fröman, G., Switalski, L.M., Guss, B., Lindberg, M., Höök,
- M. and Wadström, T. (1986) In Lark, D.L. ed. Protein-Carbohydrate Interactions in Biological Systems. Academic Press, London, pp. 263-268.
- 12. Fröman, G., Switalski, L.M., Speziale, P. and Hook, M. (1987) In press. J. Biol. Chem.
- 25. Hunter, W.M. (1978) Radioimmunoassay. In: Wier, K.M. ed. Handbook of Experimental Immunology. London Blackwell. 14.1-14.40.
- 1. Hynes, R.O. (1985) Annu. Rev. Cell Biol. 1, 67-90.
- 2. Hynes, R.O. (1986) Sci. Ann. 254, 42-51.
- 6. Kuusela, P. (1978) Nature 276, 718-720.
- 24. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., Biol. Chem. 193, 265-275.
- 13. Löfdahl, S., Guss B., Uhlén, M., Philipson, L. and lindberg, M. (1983) Proc. Natl. Acad. Sci. USA 80, 697-701. 26. Maniatis, T., Fritsch, E.F. and Sambrok, J. (1982). Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory, New York.

65

60

5

10

15

20

25

35

40

*50* 

- 23. March, S.C., Parikh, I. and Cuatrecasas, P. (1974). Analyt. Biochem. 60, 149-152.
- 27, Maxam, A.M. and Gilbert, W., (1977), Proc. Natl. Acad. Sci., USA, 74, 560.
- 28. Merrifield, K.B., J. Am. Chem. Soc., 86, pp.304, (1964)
- 19. Messing, J. and Carlsson, J. (1984). J. Biotechnol. 1, 253-264.
- 22. Miekka, S.I., Ingham, K.C. and Menache, D. (1982). Thromb Res. 27, 1-14.
  - 15. Nilsson, B., Abrahamsén, I. and Uhlén, M. (1985). EMBO J. 4, 1075-1080.
  - 16. Nilsson, B., Moks, T., Jansson, B., Abrahamsén, L., Elmblad, A., Holmgren, E., Henrichson, L., Jones, T.A. and Uhlén, M. (1986). Protein Engineering, In press.
  - 21. Norrander, J., Kempe, T. and Messing, J. (1983). Gene, 26, 101-106.
- 14. Nossal, N.G. and Heppel, L.A. (1965). J. Biol. Chem. 241, 3055-3062.
  - 3. Ruoslahti, E. and Pierschbacher, M.D. (1986). Cell, 44, 517-518.
  - 10. Rydén, C., Rubin, K., Speziale, P., Höök, M., Lindberg, M. and Wadström, T. (1983), J. Biol. Chem. 258, 3396-3401. 7. Wadström, T., Switalski, L., Speziale, P., Rubin, K., Rydén, C., Fröman, G., Faris, A., Lindberg, M., Höök, M., (1985), In Jackson, G.J. (ed), Pathogenesis of Infection. Springer Verlag, Berlin, Heidelberg, New York, Tokyo, pp. 193-207.
  - 4. Woods, A., Couchman, J.R., Johansson, S., and Höök, M. (1986), EMBO J. 5, 665-670.
  - 5. Yamada, K.M. (1983), Annu. Rev. Biochem. 52, 761-799.

#### 20 LEGENDS TO THE FIGURES

15

35

40

45

55

65

Fig. 1A. Affinity chromatography on fibronectin-Sepharose

A lysate (86 ml) obtained by cold osmotic shock of the E. coli clone pFR001 was mixed with 29 ml of 2 M ammonium acetate. The sample was then applied to a column (1.9 x 5.7 cm) equilibrated with 0.5 M ammonium acetate at a flow rate of 50 ml/h. After the application of the sample the column was washed with four column volumes of 0.5 M ammonium acetate at a flow rate of 20 ml/h. At the same time the sensitivity of the UV-monitor was increased by a factor of five. The material eluting between 200 and 220 ml was pooled, neutralized with ammonium hydroxide and dialysed against 10 mM ammonium acetate, pH 7.6.

Fig. 1B. <u>lon-exchange chromatography</u>

A sample (10 ml) of the dialysed material from the affinity-chromatography described in Fig. 1A was applied to a 1ml Mono Q (Pharmacia, Sweden) anion column equilibrated with 10 mM ammonium acetate, pH 7.6. The flow rate was 2 ml/min and the column was eluted by a liner increase in the concentration of ammonium acetate of 25 mM per ml. The two peaks (I and II) were pooled as indicated in the figure.

Fig. 2. Polyacrylamide gel electrophoresis of materials from the different purification steps of an osmotic shock lysate of E. coli pFR001

Material applied (lane 1) to the affinity column (fibronectin-Sepharose), unadsorbed (lane 2) and adsorbed (lane 3) material. Ion exchange chromatography of affinity purified material on a Mono Q FPLC column (Pharmacia, Sweden): pool I (lane 4) and pool II (lane 5) as marked in Fig. 1B.

Fig. 3. Restriction map, subclones and deletions of the insert in pFR001

(A) Restriction map of the 6.5 kb insert. (B) various subclones constructed in order to determine the region of the gene which codes for the fibronectin binding activity. (C) Deletions made from either the 3' or the 5'end of the <a href="EcoRi-PstI-fragment">EcoRi-PstI-fragment</a> by treatment with exonuclease <a href="Bal31">Bal31</a> (see text for details). The fibronectin binding activity for the differnt gene products is indicated.

Fig. 4. Polyacrylamide gel electrophoresis of the ZZ-FR pro-tein

Protein A (Sigma Chemical Co, St. Louis; lane A) and the ZZ-FR fusion protein (lane B) were reduced and subjected to electrophoresis in SDS on a 5-15% polyacrylamide gel. The gel was subsequently stained with Coomassie blue. In lanes C & D the ZZ-FR fusion protein and protein A, respectively, were fractionated by SDS-electrophoresis on a 5-9% polyacrylamide gel, electroblotted to nitrocellulose paper and probed with <sup>125</sup>I-labelled 29 kD fibronectin fragment as described (Fröman et al, 1987). Arrows indicate the migration distance of standard proteins of known molecular weights.

Fig. 5. Affinity chromatography of the ZZ-FR protein

The ZZ-FR fusion protein (0.6 mg; panel A) and protein A (Sigma Chemical Co; 0,5 mg; panel B) were applied to a 7 ml column of Sepharose 4B CL substituted with 29 kD fibronectin fragment. The column was washed with 0.5 M NaCl in PBS and subsequently eluted with 6 M GuHCl in PBS. Fractions of 2 ml were collected and assayed for protein using the BioRad system.

Fig. 6. Polyacrylamide gel electrophoresis of the ZZ-FR fusion protein preparation, fractionated by affinity chromatography.

Material not bound (lane A) and bound and eluted (lane B), respectively, from the 29 kD affinity column was analyzed by SDS-gel electrophoresis on 5-15% polyacrylamide gels. The gel was subsequently stained with

Coomassie blue. Arrows indicate the migration distance of standard proteins of known molecular weights.

#### Fig. 7. Inhibition of binding 1251-fibronectin to bacterial cells.

Staphylococcal cells (5x10<sup>7</sup>) of strain Newman (panel A) or strain 8325-4 (panel B) were incubated with 5x10<sup>4</sup> cpm of <sup>125</sup>I-labelled intact fibronectin (o-o) or 29 kD N-terminal fibronectin fragment (Δ-Δ) in PBS supplemented with 0,1% BSA, and 0.1% Tween<sup>R</sup> 80 in a total volume of 0.5 ml for 1 hr in the presence of increasing amounts of ZZ-FR fusion protein or protein A (••). For further details of the binding assay used, see Fröman et al (1987). The amounts of <sup>125</sup>I-radioactivity associated with bacterial cells was quantitated and the extent of fibronectin binding calculated. One hundred percent binding represent <sup>125</sup>I-ligand bound to bacteria in absence of inhibiting protein and 0% binding corresponded to radioactivity recorded from incubation mixtures without bacteria.

Fig. 8A. Sequence of nucleotide coding for fibronectin binding protein.

The nucleotide sequence coding for the fibronectin binding protein together with its corresponding amino acids is given. The different 38-amino acids repeats are marked, as well as appearing following almost four complete 14 amino acids repeats. The restriction sites Ball-Hincll-Pvull have been noted in the figure, as well as have the amino acids sequences corresponding to the different nucleotide sequences.

Fig. 9 The fibronectin binding ability of a chemically synthezised polypeptide.

The fibronectin binding ability of the chemically synthezised 38 amino acids polypeptide according to Example 2 together with the fibronectin binding ability of the fragments of said polypeptide have been tested. (\*-\*) denotes the polypeptide corresponding to the 38(2) repeat of the amino acids sequence; (\*-\*) denotes the polypeptide corresponding to amino acids 1-19 of the amino acids sequence; (o-o) denotes the polypeptide corresponding to amino acids 20-38 of the amino acids sequence; ( $\Delta$ - $\Delta$ ) denotes the polypeptide corresponding to amino acids no. 9-30 of the amino acids sequence; and (---) the polypeptide mixture comprising the polypeptides of amino acids 1-19, amino acids 20-38, amino acids 9-30. The binding ability in percent has been plotted against  $\mu g$  of polypeptide added.

#### Claims

- 1. Hybrid-DNA-molecule comprising a nucleotide sequence from <u>S. aureus</u> coding for a protein or polypeptide having fibronectin binding ability.
- 2. Plasmid or phage comprising a nucleotide sequence from <u>S. aureus</u> coding for a protein or a polypeptide having fibronectin binding ability.
- 3. A plasmid pFR001 as contained in the E. coll strain 259 having the deposit number DSM 4124.
- 4. An E. coli strain expressing said fibronectin binding protein.
- 5. A microorganism transformed by recombinant DNA molecule of claims 1-3.
- 6. Hybrid-DNA-molecule according to claim 1, characterized in that it comprises one or more of the following nucleotide sequences

GGC CAA AAT AGC GGT AAC CAG TCA TTC GAG GAA GAC ACA GAA GAC AAA CCT AAA TAT GAA CAA GGT GGC AAT ATG GTA GAT ATC GAT TTT GAT AGT GTA CCT CAA ATT CAT

GGT CAA AAT AAA GGT AAT CAG TCA TTC GAG GAA GAT ACA GAA AAA GAC AAA CCT AAG TAT GAA CAT GGC GGT AAC ATC ATT GAT ATC GAC TTC GAC AGT GTG CCA CAT ATT CAC

GGA TTC AAT AAG CAC ACT GAA ATT ATT GAA GAA GAT ACA AAT AAA GAT AAA CCA AGT TAT CAA TTC GGT GGA CAC AAT AGT GTT GAC TTT GAA GAA GAT ACA CTT CCA AAA GTA

- 7. Plasmid or phage comprising one or more nucleotide sequences according to claim 6.
- 8. Microorganism containing at least a plasmid or phage according to claim 7.
- 9. A method for producing a fibronectin binding protein or polypeptide, wherein a) at least one hybrid-DNA-molecule according to claim 1 is introduced into a microorganism, b) said microorganism is cultivated in a growth promoting medium, and c) the protein thus formed is isolated by means of an affinity chromatography on a column with fibronectin bound to an insolubilized carrier followed by ion exchange chromatography.
- 10. A chemical synthezising method for producing a fibronectin binding protein or polypeptide according to claim 1, whereby an amino acid residue is built up based on said nucleotide sequence encoding for said protein or polypeptide, starting from the C-terminal histidin, which is stepwise reacted with the appropriate amino acid, whereby it is finally reacted with glycine at the N-terminal end, to form the fibronectin binding protein or polypeptide.
- 11. A fibronectin binding protein or polypeptide comprising at least one of the amino acid sequences

65

10

15

20

25

30

35


40

45

50

55

	0 294 349
	Gly Gln Asn Ser Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu Glu Asp Lys Pro Lys Tyr Glu Gln Gly Gly Asn Ile Val Asp Ile Asp Phe Asp Ser Val Pro Gln Ile His
5	Gly Gln Asn Lys Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu Lys Asp Lys Pro Lys Tyr Glu His Gly Gly Asn Ile Ile Asp Ile Asp Phe Asp Ser Val Pro His Ile His
	Gly Phe Asn Lys His Thr Glu Ile Ile Glu Glu Asp Thr Asn Lys Asp Lys Pro Ser Tyr Gln Phe Gly Gly His Asn Ser Val Asp Phe Glu Glu Asp Thr Leu Pro Lys Val
10	
15	
20	
<i>25</i>	
30	
35	
40	
45	
50	
55	



F16. 1A




FIG. 1B

## 1 2 3 4 5

gel top —




FIG. 2

### RESTRICTION MAP

# Clai Kpni pvuli Sau3A Psti EcoRi Clai Bali Hincii Psti Sau3A


D 1 2 3 B SUBCLONINGS	4	,5 6	kbp Expression
<u></u>		EcoRI-Ps	
-		EcoRI-Cl	aI -
		ClaI-Cla	ı -
		BalI-Pvu	11 +
<b></b>	<b>-</b>	BalI-Hin	cII +
		HincII-p	vuII -
C Bal 31-Treatments		Number	
from	····	23	+
3' end		22	+
		21	-
		20	-
from		56	+
5' end		55	-

FIG. 3

D

	A	В	C
200K -			200K
116K	-		
93K →			116K
66K 🛶			93K <del>→</del>
45K <del>→</del>	V.		66K —
31K	•		45K →
21.5K -			31K
			21.5K
			14.4K

F16.4



F1G.5

F16.6





FIG.7

FIG. 8A:1

-21	10 194	40	70	100	130 554	160 644	190	220	250 914	100	310 094	340 184	370	30.4	4 3 0 6 5 4	460 544	34	2.4	5.0	5 8 Q
•	.,							Ν.ω	14 61	10	F 0	11	12	7 6	4.4	4.0	7 .5	5 1	2 T	2 6 1
A14 GCA	G1u GAA	Tyr	Gln	9 U	r d o	Asp	Val GTA	Val GTA	Thr	G 1 y G G A	Ala GCC	Thr	ASD	Leu TTA	Asp Gat	Asn	Th r ACA	7 G	20	Thi
G1 y GGA	Val G	r G	Ala G	Asn s	Arg T Aga a	Thr A	Ala V GCG G	61y V 660 6	TYF T	Asn G AAT G	Tyr A Tat G	Thr T ACG A	Asn A	Asn L Aat t	Thr As	<b>ω</b> #	O. F	ASP TY	3P TV	Ser TI
Leu TTG	The V	Arg S CGA T	O Pr	ASP A GAC A	0 5	Gly T GGT A	Arg A CGA G	w E	to 4	N H	<b>L</b> F4	10 et	5. F4	~ 17	Gly TI GGT A	rp Asi	Glu As GAA GA	9 ₽	14 AS	
Ly 8 AAA	H #1	h E	Gln T	Gln A CAA G	ln AG C	14 (5)	gin A CAA G	hr Bi	Le Ar	Gin Th	Asn Ty Aat Ta	ly Ly	3 u G1	in Le	Asn G	H H		o ii	11 P	u Glu A GAA
HIS	The Th Aca Ac	Glu Th GAA AC	o K	Ser G TCT C	Ala GI GCA CA	Glu Th Gaa ac	GLY G	Sn Th	YS IL	1 N C	5-17	Asn G1	r Le	y As		u Thr	T LVS	T GAS	a Asp T GAT	e Glu e Gaa
Lys	en (7	GAA G	Ala P GCA C	Gln s	<b>⊣</b> છ	Hυ	Ala G	A A AA	Gly Ly GGA AA	Thr V	18 G1	C FI	Glu Ty	r 61	r Lau	ir Leu	u fyt A TAT	10.0	a III	o Pha
AFG	GIN LY	o 4	Gln A	Thr G	Glu Va	Lys Va AAA GT	# E4	In Va	> F4	LYS THAAAA	T AT	A A	Ø ₽	G AG	u fyr G faf	H Th	e Glu T GAA	r Thr A ACT	14 K	4 C C C C C C C C C C C C C C C C C C C
LIGAT	<b>∃</b> €	IS IL	4	14.00		et 13	G H	n As	198		9 6	B Pro	e Ph	n Me	y 61	Y TY	a Ph	a Sa	21 th	o Ile A ATT
61y 1	14 G1	II HI	A V A	A AC	A GT	14 P	u Pro	r As	u Glu	P Pro	s As	e Lys T AAA	g Ile G ATA	r Asn T AAT	P Gly T GGA	9 G1Y A GGA	n Lys F AAA	7 C.	4 P P P P P P P P P P P P P P P P P P P	6 P C C A
Tyr G	4 K	T AA	S ALA	s Glu	r Gln	T AB	1 GIu	u Ser	1 Leu	e Asp T Gat	r Lys T AAA	e Ile T ATT	1 Ar	1 Se	r Asp r gat	P AG	ብ እ <u>ነ</u> ብ	7 A B B B B	18 45 15	5 AAT
A 6 G 1	a Ala	n Va	ro Ly	1 Ly	u Thr	1 3 6	s Val A GTA	r Leu T TTA	u Val	T AT	a Ty	a Phe A TTT	s Val	1 Thr	S TYT C TAT	8 8	4 4	5 4	44	19 E
Leu A	a Ala T GCA	r As	LA Pr	9 VA A GT	A GAL	u Ala A GCT	n Lys T AAA	e Thr	y Glu T GAA	u Phe A III	Lys T AAA	1 Ala	o Lys	u Val A GTC	G H	r Tyr T TAT	cAA	1 G1u 1 GAA	1 C 1 C	11 to 1
ASD L	u Ali	A Th	∢ 0	o Arg T CGA	1 Ala	8 G L	\$ <b>X</b>	다	9.00	n Ceu	T GTT	s Val	Pro A CCA	Glu A GAA	Cal Car	4 t	119	333	21.5	2 12
ASD A AAC A	8 G.	r Ala T GCA	u Glu A GAA	s Pro	n Val A GTC	\$ €	n Thr F ACA	e Asp F GAC	a Thr	a Asn F AAT	A G	r His G CAT	n Glu T CAA	LYS	CTT	TAT	II .	610	TI S	# (1 17 E1
n d	P L	r Thr	r Glu	a Lys	n Gln r CAA	A ALA	n Asn C AAT	r Phe C TTT	t Ala	I Ile	Leu	8 E	A S	TTT	TAT	LyB	000	7.4 L	Thr	11 (1) 12 (1) 13 (1)
r Ly	A A	A ACA	Thr A ACT	Ala A GCG	Asn AAT	a Glu G GAA	\$ \$	ቲያ ቴኔ	A A	Glu	GAA	Phe	61 y	Lys	Thr	ተሃ የ ተአተ	1. E.	Th.	ulu GAA	3.1 u
Va IA GT	y Gln A CAA	Gln	Thr	G G Lu	G1n CAA	A1 GC	Ris	ASP	GTA	CTA	Lys	AGA	Asn	Ser	Ly s aaa	Leu	Asn TAG	The ACT	I 14	Ph.
T'itaaagggagatatitat	90	Thr	Val GTA	Glu	Thr	Val	G14	Gly	Val	61u 64A	Ser	Asn	61n C&G	Thr	ASP GAT	gln caa	Lys	Val Gta	Tre	771 73.0
GATA	Met	GAA	G1n CAA	Lys	Ala	ASP	Glu	Gla	Ser	Ala GCT	Thr	ASD	Asn	Asp gat	Leu	Glu	61u 686	Leu	G1.7 GGA	61.4 65.3
GGGA	61y 666	Ser	Thr	V41 GTT	LYS	Ala	11e Att	His	Gly GGT	Thr	G1n CAA	Ala GCG	Ser	The	Asn	Pro	7.8n 7.4.7	ABB	ASPGAT	612
Tara	Val	Thr	Ala	Val	LYS	Ser	Ser	Leu TTA	Asn	Val Gta	G A A	Ly s Aaa	Gly GGT	Th F ACG	Glu	His	617 662	Lys	Val	Val
<	Val GTT	Lys	ABD	G1u GAG	Pro	A F G A G A	Gly	01.v 66.t	Ly s aaa	Asp Gat	GA to	Asn AAT	Ly s All A	Adn	Ile Ata	61y 66a	355 350 350	SAP GAP	Tyr Tar	1117
TTTG	Ile	AEn	SOF	Glu GAA	Thr	Thr ACA	Ile Att	Asn	Ile ATT	Val GTT	Asn	Phe TTT	Met ATG	3.1.4 GCA	Asn	Val	4 () 4 ()	7 : r 7 A F	. T. D.	0.1 y
GAAT	Met	A & P GAT	Pro	Lys	Leu	Val GTG	Glu GAA	61u GA6	G l u G A A	Ly s AAG	Leu CTA	Thr	Lau TTA	17. r 15.7	Leu	Met ATG	Ly s 2004	ala Gas	317	Mla 3CA
LAAT	Thr	Thr	Gln	Val GTT	ASPGAT	Arg CGT	Val GTA	Pha T'T	Pro	Asp Gat	Th r	G1 u GAG	Thr	Val GTA	Ser	G1n CAA	AAT		 	612 653
VAAT	G17 GGA	ALAGCT	Glu	Thr	Val GTA	Pro	Thr	Lys Aaa	V41 GTA	Gln Cåå	Se f TCA	Ile	917 663	Ser	Ty c Tat	Thr	Ser	Thr	: 10 : 10 : 10 : 10	3 9 0 K
YAR	Leu	Ser	Thr	GIII	Gln	Ly s AAG	val GTT	Leu TTG	Lys Ann	Ile	The	Se r TCG	Thr	Lys	Ser	AGA	Tyr	CTT.	Asp .	7 E S
GTT.	Phe TTC	Asn	Val GTA	110 ATA	AFG	Ser	Lys AAA	Lys	AGA	Asp	Ile ATA	GLY	Val	Ala	617 668	Phe /	Leu TTA 7	The 1	110 A	Value GTS
tgcatttaattaaaaaaattaatgaatttigc	Val GTA	G1y GGG	Thr	Asb	GID	GAA	Ser	TYL	Ala	Asn	Thr	Asn C	Thr A	Ile A	ASD GAAT	ASP E	Val L GTT T	ה לגם האא	514 1 GCT 3	Ala V Jer J
TTTA	Ser	ASD	Ala	Ala	ASP	Ser TCA	Thr :	L78 1	Thr A	The A	GIn 1	Leu A	Val 1 GTG A	ASP I GAC A	Asn A	Val A GTT G	Leu V TTA G	Lys G	Phr a	Phi A
rgca	Ala GCA	GAA	Ash	Pro CCA	61y ,	Ala S GCA 7	Val 1 GTA A	Ceu C	Ser T	Phe 1 TTT A	Asn G	Asn L AAT T	Ser V Aut G	Glu A GAA G	Gln A	Glu V GAA G	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	fle L	Han TH	His P
•	70	5.5	~ ~			~ 0	> U	u O	a t	<u>а</u> (н	~ ~	< <	s «	כי כי	g Ú	9 9	פֿי פי	₩ <b>,</b> '\$	≘ છ	# 13

F16.8A.2

04	04	04	04	04	04	0 4	04	04	07	0 4	07	04	1.2	•
61 199	208	217	70	73	76	79(	262	85 271	280	289	298	307	98 318	328
Leu	Thr	His	Ile Att	Gln	glu GAA	Thr	Pro	Val GTA	Ser AGT	Pro	Gla	Leu TTA	CAA	
Asn I	Thr 1	Asn E	ASP ]	Glu C	Thr G	His 1	Leu I	Glu 7	Pro S	Lys I	Pro CCA C	Gly I	[AAA]	
Ser /	TYT TAT	Asn A	Val /	Tyr TAT	ASP GAT	Lys 1	Thr A	Pro CCA C	Val GTG	Lys AAA	Lys AAA	CTA	ATAT	
Glu	Glu	Lys	His	Lys	glu GAA	Asn	ASP	Thr	GAA	Pro	Lys	Ile	Taaacaaaaattgacgggttatttcataaattatatgaagtaagcctgtttttttt	
Thr	LY 8 AAA	Thr	Ser	Pro	glu GAG	Phe	glu	910	Fro	Glu	Thr	Ser	GTTT	
Thr	Thr	ILB	Asn	LYS	Phe TTC	Gly	Glu	Pro	Thr	Glu	Pro	Phe	GCCT	AGT
Val	Asp Gat	glu gaa	glu gaa	Asp	Ser	His	Phe TIT	Thr	P r o C C G	Lys	Ala	Leu	GTAA	AACT
Gln	glu gaa	Glu	glu gaa	Glu	Glu	Ile	ASP	Pro	Pro	Ala	VA1 GTG	91y 96a	TGAA	TTT
01y 661	Val GTT	Val	Ile ATC	G1 u	Asn	His	Val GTT	Pro	Thr	7 L	Ala GCA	61y 66c	FTAT?	AGAAT
Gly GGT	The	Pro	Glu GAA	Thr	Gly	Pro	Ser	Val GTG	Pro	Pro	Ly s aaa	Phe	FAAAT	AGTT
Gly GGT	Thr	G1y GGA	G1u GAA	ASP	Lys	Val	Asn	Ile	Thr	Val GTA	Val GTT	Leu	TTCA:	AT.AA.
Pro	His	Gln	Ile	Glu	Asn	Ser	His	Pro	Glu GAA	Pro	Lys	Me t ATG	TTAT'	AGAG.
Asn	Asp Gat	Ala	Val Gre	Glu GAG	Gla	Asp GAC	GLY	Pro	Pro	Ř.	Glu	Gly GGT	G G G T	ACTG.
Thr	Ser	Gla	Asp	Pha	61y 667	Phe	G1y GGT	Thr	Glu	G 1 y G G T	Asn	Lys aaa	TGAC	ACGA
ASP	Val	Gly	Tyr	Ser	HIS	ABP	PPP	Thr	Ser	Pro	Ile	Asn	AAAT	GATA
G1u GAA	Ala	His	Asn	Gla	Ile ATT	IIA	G. B.	ABP	Pro	Glu	G1u GAA	Thr	ACAA	GALT
G1u GAA	G17	Glu	G1y GGG	Asn	GIN	ASP	Tyr	Glu GAA	GTA	Ala	II.	Ser FOR		TGAT
TYF	Thr.	GAA	His CAC	G1y 967	Pro	Ile ATT	Ser	Glu	glu GAA	Pro	GTT	Glu	TAA	TGTC
Glu	Val	Pro CCT	G1y	Ser	VA1	II ATC	Pro	ATT	Pro	Val	Pro	GAA	Ala GCA	TTTA
VAI	ATT	Leu	ASB	ABn AAT	Ser	Asn	LYS	Thr	Thr	61u	Thr	GIY	LYB	TTGG
Val GTT	6 61y	Glu	GAA	Gln	Asp GAT	GIY	ASP AGAT	Gln CAA	P CCA	Pro	VAI	. G17	His	TT IV
GAT	Lys	Asp GAT	Thr.	912	TTT	4 G14	Lys AAA	Gln CAA	Pro	Thr ACA	Val	Thr	Asn	TTGC
Ala GCT	Thr	v Val	4 66A	1 G1y	ASP	His CAT	Asn AAT	61y	Thr ACG	Pro	Lys	GAA	Lys	CTGA
HIE	1 Ser	Leau TTA	Leu TTA	Glu GAA	I ATC	GAA	Thr	Glu GAA	Pro	Pro	61y	Pro CCT	Lys	TTT
His A CAT	d Glu	GAA	G G T G G T	TYE	ASP AGAT	TYE 3 TAT	A GAT	Asn AAT	Thr ACA	The	G1a CAA	Leu	Asn	AGTG
Lys	GAA	1 11e	Ser	G1y GGT	Val	LYB	61u	CAA	Glu	Pro	Glu	Glu	Arg Aga	TTAG
1 Ser F TCA	ASP F GAC	r Cre	r His r CAT	Leu	r Arc	Pro	Glu F.GAA	61y	Pro CCG	Thr ACT	Val	S OF	Arg	AAAA
u Asn A AAT	u Phe A TTT	r Asn T AAT	e Ser F FCT	r Glu T GAA	y Asn C AAT	P Lys	e Ile r Atr	L Ser	r Glu r GAG	Glu GAA	Fro CCA	LYS	Leu TTA	atttctaatagaaaattagagtgtttttgattg-tt ;attggtttatgtctgatgatgattaaacgaactgagataaagttagaatttaaactagt
s Glu T GAA	1 Glu F GAA	u Ser A AGT	s Ile T ATT	s Ser G AGT	Y 61Y F 66C	B ASP A GAC	u Ile A ATT	S VAL	A AGT	a CCA	r Lys	Lys P AAG	Leu A TTA	rtci
His	Val	Glu GAA	His	Lys	GGT	Ly 8 AAA	Glu	Ly 3 AAA	S S	Glu	Ser	SOL	Ala GCA	AT



ij